News
New York, NY—November 21, 2019. Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company has received the second $3 million tranche of the $10 million Series A funding round from Shanghai Fosun Pharmaceutical Co., Ltd. (“Fosun Pharma”). The focus of this strategic investment is the advancement of the HCC Panel toward commercial launch in the United…
MedTech Innovator Showcase Announcement 6.17.19
News | Glycotest Diagnostics